CC
ABBV icon

Callan Capital’s AbbVie ABBV Stock Holding History

Callan Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.55M Buy
7,408
+1,292
+21% +$251K 0.11% 85
2024
Q4 		$1.09M Sell
6,116
-367
-6% -$67.5K 0.08% 104
2024
Q3 		$1.28M Buy
6,483
+420
+7% +$78.4K 0.09% 102
2024
Q2 		$1.04M Buy
6,063
+66
+1% +$10.9K 0.09% 107
2024
Q1 		$1.09M Buy
5,997
+759
+14% +$131K 0.1% 96
2023
Q4 		$812K Sell
5,238
-577
-10% -$84.1K 0.08% 105
2023
Q3 		$867K Buy
5,815
+1,260
+28% +$185K 0.09% 86
2023
Q2 		$614K Buy
4,555
+607
+15% +$89K 0.07% 98
2023
Q1 		$629K Sell
3,948
-1,081
-21% -$165K 0.07% 96
2022
Q4 		$813K Buy
5,029
+2,441
+94% +$374K 0.1% 88
2022
Q3 		$347K Buy
+2,588
New +$371K 0.06% 97

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Callan Capital's ABBV Position: Q1 2025 in Review

Callan Capital increased its AbbVie (ABBV) stake by 21% in Q1 2025, buying an estimated $251K and bringing the position to 7,408 shares worth $1.55M. The position accounts for 0.11% of the portfolio, ranked #85.

Callan Capital first reported a position in ABBV in Q3 2022 and has held it in 11 quarters since. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Callan Capital held 7,408 shares of AbbVie worth $1.55M as of Q1 2025.
  • Callan Capital bought 1,292 AbbVie shares in Q1 2025, an estimated $251K.
  • AbbVie made up 0.11% of Callan Capital's portfolio in Q1 2025, its #85 holding.
  • Callan Capital first reported a position in AbbVie in Q3 2022 and has held it in 11 quarters since.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.